On April 30, 2026 Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, reported its 2025 financial results, as approved by the Board of Directors on April 27, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Philippe Genne, co-founder, President and Chief Executive Officer of OPM said: "2025 is a pivotal year for OPM, marked by the maturation of our clinical assets—particularly OPM-101 and OPM-201—and by a strong refocusing of our investments on our priority programs. OPM-101 continues its development in immuno-oncology with the approval to initiate the REVERT study, while OPM-201 confirms its strategic potential in Parkinson’s disease with the support of the Michael J. Fox Foundation. These advances reinforce the positioning of our programs as mature and attractive assets for industrial partners. In an environment where funding remains constrained, we are simultaneously maintaining rigorous management of our resources to secure our trajectory and maximize the value of our assets."

Karine LIGNEL, Deputy CEO and COO of Oncodesign Precision Medicine, adds: "In 2025, we strengthened our operational discipline and focused our efforts on the programs with the greatest potential to create value. The scientific progress made on OPM-101 and OPM-201 confirms the validity of our strategy, despite a funding environment that remains challenging for publicly traded biotechnology companies."

Oncodesign Precision Medicine – Income Statement

in M€

Audited data

2025

2024

Evolution

in %

in value

Revenues

0.26

0.21

+26%

0.26

Other revenues and operating income

1.55

1.43

+9%

1.55

Total revenues and operating income

1.81

1.64

+11%

0.18

Change in inventory

13.00

NS

13.00

Purchases consumed

(3.53

)

(6.51

)

-46%

2.98

Personnel costs

(2.59

)

(2.59

)

+0%

(0.00

)

Other operating expenses

(0.05

)

(0.01

)

+492%

(0.04

)

Taxes and duties

(0.06

)

(0.07

)

-21%

0.02

Net change in depreciation and amortization

(2.88

)

(0.26

)

+1013%

(2.62

)

Total operating expenses

3.89

(9.44

)

na

13.34

Operating result

5.71

(7.81

)

na

13.51

Financial expenses and income

(0.19

)

(0.15

)

+26%

0.04

Non-recurring expenses and income

Income tax

Net result

5.48

(7.21

)

na

12.69

Overview of Our Development Programs and Technologies in 2025

In 2025, OPM continued to advance its priority assets, particularly OPM-101 in oncology and OPM-201 for the treatment of Parkinson’s disease, accelerating the transition to advanced clinical phases.

OPM-101 confirmed a favorable safety and activity profile in Phase 1 and received approval to initiate the REVERT study (Phase 1b/2a) in immuno-oncology, in combination with pembrolizumab.

Meanwhile, OPM-201 has achieved key milestones with the consolidation of its data, the validation of its mechanism of action, and the signing of a strategic partnership with the Michael J. Fox Foundation, which materialized in early 2026 with significant funding (~$7 million) to prepare for its entry into clinical trials for Parkinson’s disease.

This momentum has been accompanied by a significant improvement in operational performance. Operating revenue rose to €1.81 million (+11%), consisting mainly of government grants and reversals of provisions.

A significant effort to control costs was made in 2025, particularly regarding consumable purchases (-46%), reflecting a refocus on priority programs and an optimization of subcontracting expenses. Personnel expenses remained stable, while other operating expenses remained limited.

Operating income amounted to €5.71 million, compared to a loss of €7.81 million in 2024. This change includes a one-time effect related to the recognition of a positive inventory change of €13 million, corresponding to the consolidation of OPM-201 active ingredient inventories.

Oncodesign Precision Medicine – R&D expenditure

in M€

Analytical data

2025

2024

Evolution

In %

in value

Partnerships

0.8

1.8

– 55%

– 1.0

Licensing

2.3

4.8

– 51%

– 2.5

Total R&D expenses

3.13

6.58

– 52%

– 3.45

R&D investments declined in 2025 due to refocusing on priority programs, notably OPM-101, and a reduction in external spending on partnership and non-strategic programs.

OPM received €0.53 million in Research Tax Credits in 2025, down from 2024, due to lower R&D spending and changes in applicable tax rules.

Cash position of €2.1 million as of December 31, 2025

OPM’s cash position stood at €2.11 million as of December 31, 2025, compared to €5.27 million at the start of the fiscal year, reflecting cash outflows related to the funding of R&D activities and strategic programs during the period.

At the same time, the Company has strengthened its financing and financial flexibility, notably through convertible bonds (ORA) and government programs, while implementing a cost optimization plan that generated €5.9 million in savings during fiscal year 2025.

OPM is also continuing discussions with industrial and financial partners to secure the next stages of development.

The Company has also secured a 12-month extension of its bank loan maturity to preserve its financial flexibility. The Company’s ability to continue as a going concern beyond December 31, 2026, remains contingent upon securing additional financing, implementing further cost reductions, or entering strategic partnerships, none of which had been finalized as of the balance sheet date.

Outlook for 2026

In 2026, OPM will continue preparations for the Phase 1b trial of OPM-201 with funding from the Michael J. Fox Foundation, while continuing to seek industrial or financial partners to secure the next clinical stages.

In addition, the Phase 1b/2a trial of OPM-101 is expected to begin before the end of 2026, with the study expected to conclude by the end of 2028. Similarly, a search for partners is underway for this compound.

Finally, the other programs will progress according to the opportunities presented by the funding OPM may receive throughout the year.

Availability of the 2025 Annual Financial Report

The 2025 Annual Financial Report will be available on the company’s website on April 30, 2026.

(Press release, Oncodesign Precision Medicine, APR 30, 2026, View Source [SID1234664987])

On April 30, 2026 Labcorp Holdings Inc (NYSE: LH), a global leader of innovative and comprehensive laboratory services, reported results for the first quarter ended March 31, 2026 and updated full-year guidance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Labcorp delivered another quarter of strong results, with robust growth and double-digit Adjusted EPS growth driven by continued momentum across our Diagnostics and Central Laboratory businesses," said Adam Schechter, Chairman and CEO of Labcorp. "Health systems, providers, consumers, and biopharmaceutical customers are increasingly turning to Labcorp as their partner of choice for their complex, innovative testing needs. Our investments in advanced technologies, including robotics and AI, are improving the customer experience and transforming the way we operate. Driven by continued progress across our strategic priorities, we are raising our full year Adjusted EPS guidance to $18.03 at the midpoint of the range, an increase of $0.13."

Labcorp continues to advance its strategic priorities:

Be a partner of choice for health systems and regional and local laboratories:

Announced a nationwide strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to expand access to cutting-edge diagnostics for pediatric patients.
Completed the acquisition of select assets of Crouse Health’s Laboratory Alliance of Central New York and executed an agreement with Crouse Health to manage their inpatient labs.
Lead in specialty testing:

Announced a collaboration with Illumina to expand access to advanced genomic testing in oncology to deliver more precise biomarker insights.
Expanded nationwide access to the first FDA-approved companion diagnostic that helps identify patients with platinum‑resistant ovarian cancer who may benefit from Merck’s KEYTRUDA and KEYTRUDA QLEX.
Launched the Labcorp Fentanyl Visual Urine Test, an FDA‑cleared rapid screening test that delivers results in just 10 minutes and assesses possible fentanyl exposure for up to 48 hours.
Shape our future through technology and innovation:

Launched an AI-powered, real-world data platform with Amazon Web Services (AWS) and Datavant to accelerate Alzheimer’s research.
Expanded a collaboration with PathAI to deploy AISight Dx, an FDA-cleared digital pathology platform.
Announced a collaboration with Optum.ai to apply AI capabilities to streamline laboratory operations, improve efficiency, and enhance the patient and provider experience.
Drive personalized health solutions:

Grew Consumer Health and expanded the Labcorp OnDemand test portfolio with new tests for insulin resistance and pancreatic function, as well as customizable men’s and women’s health tests.
In May, the company will launch MyLabcorp, a secure, AI-powered mobile app that brings an individual’s test results and health data together with clinical guidance to help consumers better understand their test results.
Labcorp also remains committed to a disciplined allocation of capital. In the first quarter of 2026, the company invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid out $61.2 million in dividends. On April 9, 2026, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on June 11, 2026, to stockholders of record at the close of business on May 29, 2026.

(Press release, LabCorp, APR 30, 2026, View Source [SID1234664970])

On April 30, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and liquid offerings of the Guardant Infinity platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration reflects the growing importance of precision diagnostics in oncology drug development, where biomarker-driven approaches are increasingly essential for identifying appropriate patient populations, improving trial efficiency, and supporting regulatory approvals.

As key components of the collaboration, Guardant Health and Nuvalent plan to:

Utilize Guardant’s portfolio of tissue and liquid biopsy tests to support certain Nuvalent global clinical studies;
Evaluate opportunities to develop Guardant tissue and/or liquid biopsy assays as companion diagnostics (CDx) to support potential regulatory approvals of Nuvalent’s current investigational candidates; and,
Collaborate on the global commercialization of Nuvalent’s product candidates, if approved, and Guardant companion diagnostics across major global key markets.

(Press release, Guardant Health, APR 30, 2026, View Source [SID1234664988])

On April 30, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, reported the presentation of a poster on the NEOCYT Trial at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) to be held in Chicago from May 29th to June 3rd, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical trial is a randomized, investigator‑initiated neoadjuvant Phase 1b trial testing MDNA11, a long‑acting, "beta‑enhanced not‑alpha" IL‑2 Superkine, in combination with nivolumab (anti‑PD‑1) with or without ipilimumab (anti‑CTLA‑4) for patients with high‑risk, surgically resectable Stage III cutaneous melanoma. The study is sponsored by the non-profit Melanoma Foundation (Fondazione Melanoma Onlus) at the National Cancer Institute ‘G. Pascale Foundation’.

Details on the presentation are as follows:

Title: A Multicentre, Randomised Phase 1b Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High Risk, Surgically Resectable Melanoma – The NEO-CYT Trial
Session: Melanoma/Skin Cancers
Poster #: 488a
Abstract Number: TPS9612
Presenter: Paolo Antonio Ascierto, MD
Date & Time: May 31st, 9:00 AM – 12:00 PM CDT
Location: Hall A
Clinical Trial Registration:
eudract.ema.europa.eu/protocol.htm, identifier 2024-519010-31-00

About MDNA11

MDNA11 is a long-acting, ‘beta-enhanced not-alpha’ IL-2 Superkine specifically engineered to overcome the shortcomings of aldesleukin and other next generation IL-2 variants by preferentially activating immune effector cells (CD8+ T and NK cells) responsible for killing cancer cells, with minimal or no stimulation of immunosuppressive Tregs. These unique proprietary features of the IL-2 Superkine have been achieved by incorporating seven specific mutations and genetically fusing it to a recombinant human albumin scaffold to improve the pharmacokinetic (PK) profile and pharmacological activity of MDNA11 due to albumin’s natural propensity to accumulate in highly vascularized sites, in particular tumor and tumor draining lymph nodes. MDNA11 is currently being evaluated in the Phase 1/2 ABILITY-1 study as both monotherapy and in combination with pembrolizumab.

(Press release, Medicenna Therapeutics, APR 30, 2026, View Source [SID1234664971])

On April 30, 2026 Novocure (NASDAQ: NVCR) reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This was a very strong start to the year for Novocure and we are pleased with the progress made across our commercial and clinical programs," said Frank Leonard, CEO, Novocure. "We reached several key milestones in the first quarter and are eager to maintain this momentum as we approach numerous exciting catalysts later this year. Our focus remains on bringing Tumor Treating Fields therapy to patients diagnosed with some of the most aggressive forms of cancer, further exploring the use of our therapy to benefit patients in need, and achieving sustainable growth and profitability."

Financial updates for the quarter ended March 31, 2026:

Total net revenues for the quarter were $174.1 million, an increase of 12% compared to the same period in 2025. This increase was primarily driven by active patient growth in European markets.
The U.S., Germany, France and Japan contributed $96.0 million, $24.5 million, $22.9 million and $10.2 million, respectively, with other active markets contributing $15.7 million.
Net revenue from Germany benefitted from increased approval rates, including a one-time benefit of $2.5 million.
Net revenue from France benefitted from contract performance improvements, including a one-time benefit of $1 million.
Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $4.8 million.
Recognized revenue from Optune Lua in the quarter was $3.1 million.
Gross margin for the quarter was 78% compared to 75% in the prior year. The increase was primarily driven by lower array costs resulting from improved array utilization and lower supplier prices.
Research, development and clinical study expenses for the quarter were $58.3 million, an increase of 8% from the same period in 2025. This was primarily driven by increased costs associated with patient recruitment in the Phase 3 KEYNOTE D58 clinical trial.
Sales and marketing expenses for the quarter were $58.4 million, an increase of 5% compared to the same period in 2025. This was primarily driven by costs associated with the launch of Optune Pax in the U.S. and Optune Lua in Japan.
General and administrative expenses for the quarter were $85.9 million, an increase of 92% compared to the same period in 2025. This increase was primarily driven by a $43 million share-based compensation expense triggered by the U.S. FDA approval of Optune Pax. This non-cash expense is reported in accordance with U.S. GAAP, but the associated grant did not vest and shares were not distributed.
Net loss for the quarter was $71.1 million with loss per share of $0.62.
Adjusted EBITDA* for the quarter was $(0.3) million.
Cash, cash equivalents and short-term investments were $432.0 million as of March 31, 2026.
Operational updates for quarter ended March 31, 2026:

As of March 31, 2026, there were 4,791 total active patients on TTFields therapy globally.
Optune Gio
As of March 31, 2026, there were 4,543 active patients on Optune Gio, an increase of 9% from the same period in 2025.
The U.S., Germany, France and Japan contributed 2,250; 641; 503 and 535 Optune Gio active patients, respectively, with 614 active patients contributed by other active markets.
Optune Lua
As of March 31, 2026, there were 165 active patients on Optune Lua, an increase of 56% from the same period in 2025.
The U.S., Germany, France and Japan contributed 106; 47; 2 and 6 active patients, respectively, with 4 active patients contributed by other active markets.
Optune Pax
169 prescriptions for Optune Pax were received in the quarter.
As of March 31, 2026, there were 83 active patients on Optune Pax in the U.S.
Quarterly updates and achievements:

January 2026
Public health insurers in Czechia announced coverage for Optune Gio for the treatment of adult patients with newly diagnosed glioblastoma (GBM).
February 2026
The U.S. FDA approved Optune Pax for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.
British Columbia (BC) Cancer announced coverage for Optune Gio for adult patients with newly diagnosed GBM.
March 2026
Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua through the country’s National Health Insurance coverage. Optune Lua is approved in Japan for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who progressed on or after platinum-based chemotherapy.
Novocure announced the topline results from the Phase 2 PANOVA-4 clinical trial, evaluating TTFields therapy concomitant with atezolizumab (Tecentriq), gemcitabine and nab-paclitaxel as a first-line treatment for metastatic pancreatic cancer. PANOVA-4 met its primary endpoint, achieving a 74% disease control rate (DCR), a statistically significant improvement compared to a 48% DCR in patients treated with gemcitabine and nab-paclitaxel alone in the historical control.
2026 Financial Guidance:

Novocure’s updated guidance for the full year 2026, as of April 30, 2026, is summarized below:

Total net revenue: $690 million – $710 million (previous: $675 million – $705 million)
Adjusted EBITDA*: $(15) million – $0 million (previous: $(20) million – $0 million)
This guidance assumes full-year mid-single digit net revenue growth from Optune Gio, net revenue contribution from Optune Lua and Optune Pax, collectively, between $15 million and $25 million, a mid-70s percent gross margin, and foreign exchange rates as of March 31, 2026.

Anticipated clinical and regulatory milestones:

Topline data from the Phase 3 TRIDENT trial in newly diagnosed GBM (Q2 2026).
Decision by the U.S. FDA on the premarket approval application for use of TTFields therapy for the treatment of brain metastases from NSCLC (Q4 2026).
Complete enrollment in Phase 3 KEYNOTE D58 clinical trial in newly diagnosed GBM (Q4 2026).
Conference call details

Novocure will host a conference call and webcast to discuss first quarter 2026 financial results at 8:00 a.m. EDT today, Thursday, April 30, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, investor.novocure.com, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

(Press release, NovoCure, APR 30, 2026, View Source [SID1234664989])